Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions
October 25, 2021 08:31 ET
|
Aquestive Therapeutics, Inc.
First and only orally delivered epinephrine product candidate AQST-109 demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of allergic...
Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET
October 14, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement
October 06, 2021 17:59 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics to Participate in Three Investor Conferences in September
September 07, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement
August 09, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
Provides access to $30 million in capital contingent on FDA approval and U.S. market access for Libervant WARREN, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:...
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
August 06, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance
August 03, 2021 17:55 ET
|
Aquestive Therapeutics, Inc.
Libervant™ NDA resubmission accepted, PDUFA goal date of December 23, 2021On track to report top-line data from Phase 1 study for AQST-109 epinephrine sublingual film in second half 2021Increases full...
Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8:00 a.m. ET
July 21, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., July 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film
July 19, 2021 09:29 ET
|
Aquestive Therapeutics, Inc.
Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the...
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
June 24, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
Anticipates FDA PDUFA goal date in late 2021If approved by the FDA for US market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters WARREN,...